This glucagon resistance leads to disruptions in lipid and amino acid metabolism, resulting in excessive fat accumulation in the liver, increased oxidative stress in hepatocytes, and ultimately, the progression of NAFLD.509 Therapeutic strategies targeting this signaling pathway, such as the use of glucagon receptor antagonists, may offer new treatment avenues for the management of NAFLD. The gene discussed is GCGR; the disease is metabolic dysfunction-associated steatotic liver disease.